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1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: Effective mediators activate downstream transducers regu-
lating inflammation and angiogenesis. Correlation among mediators IL-6, IL-27, TNF-a, and
VEGF with STAT proteins at diverse clinical-pathologic stages of cirrhotic patients remains
limited.
Methods: Plasma mediators were assayed from 158 naı¨ve liver cirrhosis (LC-total group) and
144 non-LC individuals. The LC-total group included 69 hepatitis B virus-infected (LC-HBV) pa-
tients, 40 hepatitis C virus-infected (LC-HCV) patients, and 49 patients without HBV/HCV
infection (LC-NBNC). Another 144 non-LC individuals comprised 54 healthy persons (HG) and
90 chronic hepatitis patients (CH-total) as the control group. To correlate with plasma medi-
ators, 52 paired liver tissues (CH: 41 and LC: 11 cases) served for p-STAT1 and p-STAT3 immu-
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10.1016/j.jmii.2015.03.001Results: Although IL-6, IL-27, TNF-a, and VEGF were expressed significantly in CH-total versus
HG (p Z 0.011, p < 0.001, p Z 0.007, p Z 0.004, respectively) and overall viral hepatitis pa-
tients versus HG (p < 0.001, p < 0.001, p < 0.001, p < 0.001, respectively), only IL-6 presented
the strongest correlation in cirrhotic patients than noncirrhotic patients (LC-HBV vs. HG,
p < 0.001, vs. CH-HBV, p Z 0.001; LC-HCV vs. HG, p Z 0.001, vs. CH-HCV, p Z 0.031; LC-
NBNC vs. HG, p < 0.001). Over-expressed IL-6 linked with poorer liver function (albumin:
r Z 0.346, p < 0.001; bilirubin: r Z 0.271, p Z 0.001; INR: r Z 0.308, p < 0.001; Child-
Turcotte-Pugh Classification C vs. A or B, pZ 0.001, pZ 0.007, respectively), variceal severity
(p Z 0.045), and bleeding (p Z 0.047), as well as patients’ mortality (p Z 0.005). Further-
more, plasma IL-6 significantly correlated with tissues p-STAT3 expression (r Z 0.737,
p Z 0.010) (IL-27: r Z 0.078, p Z 0.820; TNF-a: r Z 0.145, p Z 0.670; VEGF: r Z 0.142,
p Z 0.678) in cirrhotic patients than noncirrhotic patients.
Conclusion: Over-expression of IL-6 reflects hepatic dysfunction and varices bleeding with
mortality, as well as correlates p-STAT3 expression in cirrhotic patients.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Hepatitis B virus (HBV), hepatitis C virus (HCV) infections,
and chronic alcohol abuse all contribute to three important
etiologies of liver cirrhosis (LC) worldwide,1,2 while dete-
riorating hepatic preservation in cirrhotic patients, varices
formation and rupture, among the complications, is
frequently a leading cause of death.3 Prone to variceal
rupture, resistance to the blood flow of the portal vein
gradually increases and induces hypertensive situation in
the portal venous system, which develops into portal hy-
pertension and results in the engorgement of the por-
talesystemic collateral vessels. Finally, these engorged
vessels can lead to the development of varices at various
gastrointestinal locations.4e6 Although the invasive modal-
ities such as esophagogastroduodenoscopy and hepatic
venous pressure gradient monitoring were introduced,7e9
they are limited in these high-risk populations owing to
being invasive procedures that could result in further vessel
or hepatic injury in clinical scenarios. Therefore, finding
noninvasive optimal biomarkers which would allow detec-
tion before varices formation or rupture and lead to a
further decrease in mortality of cirrhotic patients has
become a critical issue.
Among well-recognized mediators, biological activities
by vascular endothelial growth factor (VEGF), interleukin
(IL)-27, IL-6, and tumor necrosis factor-alpha (TNF-a) have
been implicated in regulating inflammation and/or angio-
genesis in liver diseases. VEGF can induce development of
portosystemic collateral vessels in animal studies.10e14 IL-
27 not only can act on hepatocytes against viral activity,
but also can suppress tumor proliferation.15,16 IL-6 might
reflect more active hepatic necroinflammation and be
associated with the severity of disease.17e21 TNF-a is not
only a proinflammatory cytokine,22,23 but also can regulate
the development and rupture of esophageal varices in an-
imal studies.24-29 However, the biological functions are
mediated by various types of signaling pathways. The Janus
kinase (JAK)-signal transducer and activator of transcrip-
tion (STAT) pathway has been observed, which leads to cell
proliferation, protection from apoptosis, and increasedo J-T, et al., IL-6 significantly corr
cross-sectional study, Journal ofmetastatic potential in liver disease.21 However, the in-
terrelations of biological effects among these mediators
with STATs proteins remain limited in the studies of cell
lines and animal models.10e12,27e29
To elucidate the clinical importance of IL-6, IL-27, TNF-
a, and VEGF in varices development with rupture and
mortality among cirrhotic patients, as well as their corre-
lation with STAT1 and STAT3 proteins, we conducted this
study in different clinical-pathologic stages of liver dis-
eases. Findings on biological mechanisms of these mole-
cules and their interrelations with varices and mortality
might increase our understanding to create new thera-
peutic modalities for managing liver cirrhosis.Methods
Setting and participants
After informed consent and exclusion of patients who did
not meeting the enrollment criteria, 302 patients with a
well-characterized clinical condition for plasma mediators
assay, including 158 cirrhotic patients without previous
variceal hemorrhage (LC-total group), 90 hepatitis patients
(CH-total group) and 54 healthy individuals (HG) were
enrolled at China Medical University Hospital in Taichung,
Taiwan. The period of patient enrollment was from January
2010 to March 2012 and their clinical outcomes were fol-
lowed until January 2014 to evaluate cirrhotic patients at 3-
month, 6-month, and final mortality stages. As per clinical
serological diagnoses, the LC-total group was categorized
into three subgroups, including 69 patients with positive
HBsAg for longer than 6 months (LC-HBV group), 40 patients
with positive anti-HCV Ab for longer than 6 months (LC-HCV
group), and 49 patients with negative HBsAg and antieanti-
HCV markers (LC-NBNC group). CH-total group comprised
those without LC but who are positive for HBsAg or the anti-
HCV marker for longer than 6 months, including 25 HBV-
infected and 65 HCV-infected patients. The HG group
included those without LC and negative for HBsAg/anti-HCV
marker. Another 52 paired liver tissues, including 11 LCelates with p-STAT3 expression and presents high variceal bleeding
Microbiology, Immunology and Infection (2015), http://dx.doi.org/
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HBV cases and 31 HCV cases) were obtained for immuno-
staining of STAT1 phosphorylation (p-STAT1) and STAT3
phosphorylation (p-STAT3).
The definition and severity of LC were based on (1)
abdomen ultrasonography finding combined clinical signs
with biochemical examinations, including shrunken liver size,
splenomegaly, jaundice, ascites, hyperbilirubinemia,
reversed levels of serum aspartate transaminase (AST) and
alanine Transaminase (ALT), prolonged serum prothrombin
time, and the albumin/globulin (A/G) ratio <1 etc.; or (2)
liver biopsy and histopathology showing a METAVIR score of 4.
Further classifications of disease severity were according to
theChildeTurcotteePugh (CTP) Classification rather than the
model for end-stage liver disease (MELD) score, which was
used to predict the outcomeof cirrhotic patients in general.30
In addition, the severity levels of esophageal varices were
determined according to esophagogastroduodenoscopy find-
ings and classified from Grade I (minimally elevated veins
above the esophageal mucosal surface) to Grade III (occupied
more than one-third of the esophageal lumen). The variceal
rupture meant patients accepted esophagogastroduodeno-
scopy intervention, such as sclerotherapy or band ligation,
owing to the finding of (1) active bleeding from a varix; or (2)
white nipple or clots overlying varix combined bleeding evi-
dence before the emergency room, with low hemoglobin
data. They were all admitted for further medical treatment.
The definition of 3-month (early) and 6-month (chronic)
mortality meant the cirrhotic patient died owing to disease
progression since enrollment during the study period.
The LC or CH patients who had (1) coinfection or su-
perinfection with hepatitis A virus (HAV), HBV, HCV, or
human immunodeficiency virus (HIV); (2) previous antiviral
agents, i.e. interferon, nucleotide agents, or immuno-
modulatory agents; (3) autoimmune hepatitis; or (4) pre-
vious variceal hemorrhage and received ligation or
sclerotherapy, were excluded from this study. All pro-
cedures were followed in accordance with the ethical
standards of the responsible Committee on Human Experi-
mentation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2008. The Institutional
Review Board of China Medical University Hospital, Tai-
chung, Taiwan, also approved this study.
Serological virus markers and liver biochemical
assays methodology
Serum HBV markers, anti-HCV antibodies, HBV DNA, and
HCV RNA levels were assessed by commercial enzyme
immunoassay (AxSYM, Abbott, North Chicago, IL, USA;
Abbott HCV EIA 2.0; Abbott Laboratories; Cobas Amplicor
HCV Monitor 2.0; Roche Diagnostics, Branchburg, NJ, USA).
Serum albumin, AST, and ALT, AFP, bilirubin, coagulation
tests, and creatinine were determined using an auto-
analyzer (TBA-30FR, Toshiba, Tokyo, Japan).
Estimation of plasma mediators and tissue
immunohistochemistry
Venous plasma samples obtained from peripheral vein of all
enrolled cases (for cases with variceal rupture, samplePlease cite this article in press as: Kao J-T, et al., IL-6 significantly corr
with mortality in cirrhotic patients: A cross-sectional study, Journal of M
10.1016/j.jmii.2015.03.001collected after the diagnosis by EGD within 2 days) and
immediately centrifuged and stored at 80C. Quantifica-
tion of IL-6, IL-27, TNF-a and VEGF by specific enzyme-
linked immunosorbant assay was made using commercially
available kits within 2 weeks (kits for IL-6, IL-27, and TNF-a
were from eBioscience, San Diego, CA; the VEGF kit was
from Antigenix American, Huntington Station, NY). Results
were expressed in picograms per milliliter (pg/mL); liver
tissues were fixed in 10% formalin and embedded in
paraffin. Blocks were sectioned at 4 mm for each tissue and
three pieces of each specimen stained, including one
without and two with phosphorylation according to a
standard protocol (Cell Signaling Technology, Inc. 3 Trask
Lane, Danvers, MA, USA). As a result, immunostaining of p-
STAT1 and p-STAT3 mean active form was quantified by
counting positively stained cytoplasma and nuclei of he-
patocytes per 10 high-power fields (400 magnifications)
microscopically from each specimen, respectively. Positive
immunostain was considered when S10% nuclei or cyto-
plasma of hepatocytes were stained. The immunoreactivity
expression was categorized as Level I (mean <10% nuclei or
cytoplasma of hepatocytes stained), II (mean S10% to
<25% nuclei or cytoplasma of hepatocytes stained), or III
(meanS25% nuclei or cytoplasma of hepatocytes stained).
Statistical analysis
The clinical parameters in Table 1 were expressed as
mean  standard deviation. Cytokine expression was pre-
sented as mean  standard error mean and each group of
experiments was repeated at least twice to confirm the data.
Continuous variables were assessed using the Student t-test
and Pearson correlation, with data analyzed using SPSS
version 17.0 for Microsoft Windows (SPSS, Chicago, IL, USA). A
two-sided p value <0.05 indicated statistical significance.
Results
Patients’ demographic and clinical characteristics
Table 1 shows the baseline characteristics of the three
major groups. Patients in the LC-total group were older
than those in the CH-total group and HG (55.55  13.14 vs.
50.13  14.36 vs. 42.87  13.35 years of age, respectively),
which was compatible with the distribution of liver
diseases.
IL-6 presented the strongest expression in cirrhotic
patients than noncirrhotic patients
In HBV- or HCV-infected liver diseases, four mediators were
significantly expressed in the CH-total group versus HG
(2.76  0.88 vs. 0.46  0.10 pg/mL in IL-6, p Z 0.011;
165.86  33.68 vs. 9.83  3.26 pg/mL in IL-27, p < 0.001;
67.10  23.53 vs. 1.76  1.49 pg/mL in TNF-a, p Z 0.007;
4.81  1.48 vs. 0.40  0.07 pg/mL in VEGF, p Z 0.004,
respectively) (Fig. 1) and overall viral hepatitis patients
(CH-total and LC-HBV and LC-HCV) versus HG (8.90  1.44
vs. 0.46  0.10 pg/mL in IL-6, p < 0.001; 188.89  36.21 vs.
9.83  3.26 pg/mL in IL-27, p < 0.001; 56.54  14.53 vs.elates with p-STAT3 expression and presents high variceal bleeding
icrobiology, Immunology and Infection (2015), http://dx.doi.org/
Table 1 Baseline characteristics of all enrolled cases (N Z 302)
Demographics Healthy group
(n Z 54)
CH group (n Z 90) Cirrhotic group (n Z 158)
CH-HBV (n Z 25) CH-HCV (n Z 65) LC-NBNC
(n Z 49)
LC-HBV (n Z 69) LC-HCV (n Z 40)
Age (y) (range) 42.87  13.35
(19e68)
44.2  12.41 (19e76) 52.42  14.48 (19e74) 53.04  12.86
(29e81)
53.28  11.36 (32e82) 62.55  14.13 (35e89)
Sex (Male) (%) 33 (61.1%) 18 (72%) 33 (50.8%) 41 (83.7%) 57 (82.6%) 18 (45.0%)
Varices/variceal
bleeding (n/n)
0/0 0/0 0/0 37/9 34/13 21/10
Child-Pugh score
(stage A/B/C)
// // // 18/11/20 32/16/21 11/11/18
Biochemical values
Albumin (g/dL) 4.44  0.37
(3.5e5.0)
4.27  0.45 (3.4e5.1) 4.33  0.38 (3.3e5.1) 3.29  0.73
(1.4e4.5)
3.45  0.71 (2.0e4.6) 3.05  0.76 (1.6e4.8)
Bilirubin (mg/dL) 0.8  0.23
(0.25e1.30)
0.95  0.36 (0.52e2.23) 1.0  0.52 (0.42e4.11) 4.49  5.92
(0.32e26.49)
5.80  9.87 (0.45e38.82) 3.12  4.77 (0.17e23.41)
Creatinine (mg/dL) 0.83  0.20
(0.49e1.51)
0.8  0.15 (0.59e1.03) 0.83  0.24 (0.43e1.53) 1.14  0.73
(0.42e4.36)
1.34  1.44 (0.52e8.75) 1.51  1.85 (0.35e11.21)
AST (IU/L) 21.86  6.28
(14e51)
50.6  43.53 (12e201) 73.56  79.46 (17e463) 58.31  35.25
(11e147)
146.06  332.62 (21e2098) 70.31  40.16 (23e192)
ALT (IU/L) 20.93  7.16
(10e40)
65.35  53.69 (16e218) 95.55  166.47 (13e1330) 30.24  18.17
(11e117)
150.97  524.80 (11e4200) 45.68  28.26 (12e109)
INR 0.96  0.06
(0.86e1.18)
1.02  0.07 (0.87e1.15) 1.0  0.06 (0.89e1.19) 1.39  0.41
(0.89e2.58)
1.47  0.70 (0.89e3.93) 1.32  0.36 (0.92e2.57)
Platelet (103/mL) 245.46  57.22
(138e351)
191.11  47.73 (101e283) 188.95  52.67 (92e378) 95.6  54.41
(23e252)
102.73  61.98 (26e387) 97.75  47.24 (33e214)
AFP 2.78  1.45
(1.0e8.02)
15.33  28.76 (0.99e104.24) 14.58  75.28 (1.21e611.11) 8.78  12.64
(1.24e76.72)
28.22  81.67 (1.24e570.18) 9.21  10.6 (1.66e64.93)
Virological values
HBeAg (þ) (%) 0 11 (44%) 0 0 9 (13.0%) 0
Viral loads
(copies/mL)
0 6.95  108  2.59  109
(<34.92e1.27  1010)
8.95  106  1.95  107
(<40.5e1.33  108)
0 2.67  107  1.15  108
(<34.92e6.40  108)
4.70  106  7.82  106
(<40.5e2.01  107)
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Figure 1. The expression of IL-6, IL-27, TNF-a, and VEGF in separate subgroups. * A value of p < 0.05 was defined as statistically
significant.
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+ MODEL1.76  1.49 pg/mL in TNF-a, p < 0.001; 8.86  1.67 vs.
0.40  0.07 pg/mL in VEGF, p < 0.001, respectively).
Whereas chronic hepatitis progressed to cirrhosis, both IL-6
andVEGF rather than IL-27with TNF-aprofileswereexpressed
predominantly in the LC-total group versus HG (14.40  1.96
vs. 0.46  0.10 pg/mL in IL-6, p < 0.001; 309.49  109.22 vs.
9.83  3.26 pg/mL in IL-27, p Z 0.007; 41.35  13.07 vs.
1.76  1.49 pg/mL in TNF-a, p Z 0.003; 12.09  2.21 vs.
0.40  0.07 pg/mL in VEGF, p < 0.001, respectively) and LC-
total versus CH-total groups (14.40  1.96 vs.
2.76  0.88 pg/mL in IL-6, p < 0.001; 12.09  2.21 vs.
4.81  1.48 pg/mL in VEGF, pZ 0.007, respectively).
However, IL-6 among four mediators was over-expressed
in separate LC groups: LC-HBV group versus HG
(14.63  3.32 vs. 0.46  0.10 pg/mL in IL-6, p < 0.001;
179.99  72.22 vs. 9.83  3.26 pg/mL in IL-27, p Z 0.021;
43.74  25.43 vs. 1.76  1.49 pg/mL in TNF-a, p < 0.001;
8.17  2.09 vs. 0.40  0.07 pg/mL in VEGF, p < 0.001) and
CH-HBV group (14.63  3.32 vs. 2.46  0.75 pg/mL in IL-6,
p Z 0.001); LC-HCV group vs. HG (12.81  3.36 vs.
0.46  0.10 pg/mL in IL-6, p Z 0.001; 256.09  107.02 vs.
9.83  3.26 pg/mL in IL-27, p Z 0.027; 55.16  23.29 vs.
1.76  1.49 pg/mL, p < 0.001 in TNF-a; 19.16  6.49 vs.
0.40  0.07 pg/mL in VEGF, p Z 0.006) and CH-HCV group
(12.81  3.36 vs. 2.88  1.18 pg/mL, p Z 0.008 in IL-6;
19.16  6.49 vs. 4.26  1.60 pg/mL in VEGF, p Z 0.031);
and LC-NBNC group vs. HG (15.36  3.28 vs. 0.46  0.10 pg/
mL in IL-6, p < 0.001; 535.45  325.90 vs. 9.83  3.26 pg/
mL in IL-27, pZ 0.001; 26.73  11.96 vs. 1.76  1.49 pg/mL
in TNF-a, pZ 0.044; 11.83  3.66 vs. 0.40  0.07 pg/mL in
VEGF, p Z 0.003) (Fig. 1).
IL-6 presented the strongest correlation with
fibrosis severity in biopsy patients
For correlation between fibrosis scores of tissues with
serum mediator expressions in 52 biopsy cases (ScorePlease cite this article in press as: Kao J-T, et al., IL-6 significantly corr
with mortality in cirrhotic patients: A cross-sectional study, Journal of M
10.1016/j.jmii.2015.03.0011Z 20 cases, Score 2Z 13 cases, Score 3Z 8 cases, Score
4 Z 11 cases), only IL-6 showed a positive correlation with
fibrosis severity (r Z 0.313, p Z 0.024).
Over-expression of IL-6 significantly correlated
with deteriorating liver condition in cirrhotic
patients
Among four mediators, IL-6 overexpression not only pre-
sented the strongest correlation with clinical factors asso-
ciated with liver function, such as albumin (r Z 0.346;
p < 0.001), bilirubin (r Z 0.271; p Z 0.001), and interna-
tional normalized ratio (INR) levels (r Z 0.308; p < 0.001)
(Table 2) but also with liver preservation according to the
CTP classification (24.08  3.92 vs. 8.06  2.1 pg/mL,
pZ 0.001 in Class C vs. A; 24.08  3.92 vs. 9.55  3.51 pg/
mL, p Z 0.007 in Class C vs. B). By contrast, IL-27, TNF-a,
and VEGF could not show significant statistical difference in
each group (Fig. 2).
Raised IL-6 expression presented significant
correlation with varices formation, severity, and
rupture in cirrhotic patients
Although IL-27 and TNF-a same IL-6 showed significant
expression in presence (n Z 92 cases) versus not (n Z 66
cases) of varices in all cirrhotic patients (16.47  2.65 vs.
11.52  2.86 pg/mL in IL-6, pZ 0.045; 413.60  179.01 vs.
164.36  76.73 pg/mL in IL-27, pZ 0.027; 63.18  21.92 vs.
10.94  5.01 pg/mL in TNF-a, p Z 0.022, respectively)
(Fig. 3A), both IL-27 and TNF-a could not significantly
activate in presence (n Z 32 cases) versus not (n Z 60
cases) of variceal bleeding among patients with varices. By
contrast, only IL-6 expression significantly correlated with
variceal bleeding (22.21  4.92 vs. 13.41  3.06 pg/mL,
p Z 0.047) (Fig. 3B) and severity of varices (Grade 0/1/2/elates with p-STAT3 expression and presents high variceal bleeding
icrobiology, Immunology and Infection (2015), http://dx.doi.org/
Table 2 Correlations between IL-6, IL-27, TNF-a, and VEGF with clinical biochemical data in naı¨ve cirrhotic patients (NZ 158)
IL-6 IL-27 TNF-a VEGF
g p g p g p g p
Age (y) 0.075 0.349 0.131 0.101 0.016 0.846 0.081 0.309
Sex (male/female) 0.036 0.653 0.171 0.032* 0.093 0.247 0.263 0.001*
Albumin (g/dL) 0.346 <0.001* 0.089 0.118 0.701 0.154 0.171 0.039*
Bilirubin (mg/dL) 0.271 0.001* 0.064 0.422 0.012 0.879 0.034 0.672
Creatinine (mg/dL) 0.013 0.875 0.059 0.474 0.054 0.510 0.028 0.732
AST (IU/L) 0.101 0.226 0.003 0.968 0.045 0.591 0.031 0.709
ALT (IU/L) 0.115 0.151 0.027 0.735 0.031 0.701 0.039 0.626
INR 0.308 <0.001* 0.096 0.240 0.067 0.415 0.017 0.835
Platelet (103/mL) 0.062 0.448 0.054 0.514 0.127 0.119 0.091 0.265
AFP (ng/mL) 0.057 0.484 0.022 0.787 0.005 0.949 0.053 0.514
HBV or HCV (positive) 0.026 0.742 0.111 0.166 0.060 0.455 0.006 0.939
*A value of p < 0.05 was defined as significant.
6 J.-T. Kao et al.
+ MODEL3 Z 66/38/40/14 cases) (Grade 0 vs. 1 vs. 2 vs. 3 in IL-6
expression: 11.57  2.98 vs. 15.30  3.74 vs.
15.08  3.68 vs. 22.09  8.63 pg/mL, respectively,
r Z 0.190 and p Z 0.017; IL-27 expression: r Z 0.084 and
p Z 0.294; TNF-a expression: r Z 0.126 and p Z 0.113;
VEGF expression: r Z 0.070 and p Z 0.383, respectively).
Raised IL-6 expression presented the strongest
correlation with mortality in cirrhotic patients
Compatible with the above findings, elevated IL-6 levels
significantly correlated with mortality including 3-month
or 6-month survival (3-month vs. >3-month survival:
31.03  7.24 vs. 12.65  1.98 pg/mL, p Z 0.006; 6-
month vs. >6-month survival: 30.66  6.24 vs.
12.04  1.98 pg/mL, pZ 0.009, respectively) (Fig. 4A and
B), and also presented an important factor to predict 24-
month mortality in cirrhotic patients (p Z 0.005) such as
variceal bleeding (p Z 0.034) and lower albumin levels
(p Z 0.008) (Table 3). By contrast, elevated IL-27 andFigure 2. IL-6 expression presented significant correlation with
p < 0.05 was defined as statistically significant.
Please cite this article in press as: Kao J-T, et al., IL-6 significantly corr
with mortality in cirrhotic patients: A cross-sectional study, Journal of
10.1016/j.jmii.2015.03.001TNF-a and VEGF levels showed insignificant correlation
with mortality (Fig. 4A and B, Table 3). Furthermore, IL-6
presented better sensitivity (65.35%), specificity (71.93%),
negative predictive values (NPV) (53.95%), and positive
predictive values (PPV) (80.45%) to predict mortality than
other cytokines (53.02%, 66.67%, 7.89%, and 96.34% in IL-
27; 57.89%, 57.14%, 47.37%, and 67.07% in TNF-a;
55.32%, 76.47%, 17.11%, and 95.12% in VEGF,
respectively).
Tissue p-STAT3 showed a higher immunostaining
rate than p-STAT1 and correlated with plasma IL-6
expression in biopsy patients
To explore the clinical relationship between tissues p-
STAT proteins and plasma four mediators, we examined
the immunoreactivities expression of p-STAT1 and p-
STAT3 in 52 biopsy patients. As shown in Fig. 5A, we found
p-STAT3 presented a higher immunostaining rate (S10%
immunostaining of hepatocytes) than p-STAT1 in all liverdeteriorating liver condition in cirrhotic patients. * A value of
elates with p-STAT3 expression and presents high variceal bleeding
Microbiology, Immunology and Infection (2015), http://dx.doi.org/
Figure 3. IL-6 expression presented significant correlation with varices formation (A) and variceal bleeding (B) in cirrhotic pa-
tients. * A value of p < 0.05 was defined as statistically significant.
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+ MODELspecimens (32/52 vs. 19/52, p Z 0.003). Moreover,
increasing immunoreactivities levels of p-STAT3 rather
than p-STAT1 also significantly correlated with IL-6
expression in all LC with CH patients (p-STAT3 vs. IL-6:
r Z 0.316, p Z 0.022; vs. IL-27: r Z 0.116, p Z 0.239;
vs. TNF-a: r Z 0.228, p Z 0.105; vs. VEGF: r Z 0.329,
p Z 0.017, respectively); (p-STAT1 vs. IL-6: r Z 0.137,
p Z 0.334; vs. IL-27: r Z 0.000, p Z 0.998; vs. TNF-a:
r Z 0.129, p Z 0.364; vs. VEGF: r Z 0.094, p Z 0.507,
respectively); and LC patients (p-STAT3 vs. IL-6:
r Z 0.737, p Z 0.010; vs. IL-27: r Z 0.078, p Z 0.820;
vs. TNF-a: r Z 0.145, p Z 0.670; vs. VEGF: r Z 0.142,
p Z 0.678, respectively); (p-STAT1 vs. IL-6: r Z 0.400,
p Z 0.223; vs. IL-27: r Z 0.278, p Z 0.408; vs. TNF-a:
rZ 0.420, pZ 0.198; vs. VEGF: rZ 0.493, pZ 0.123,
respectively); (Fig. 5A and B).Please cite this article in press as: Kao J-T, et al., IL-6 significantly corr
with mortality in cirrhotic patients: A cross-sectional study, Journal of M
10.1016/j.jmii.2015.03.001Discussion
With deteriorating hepatic preservation, varices develop-
ment with rupture becomes predominant and plays a leading
cause of death among complications in cirrhotic patients.3
Although modalities such as esophagogastroduodenoscopy
and hepatic venous pressure gradient monitoring have been
developed to investigate this fatal complication in clinical
scenarios,7e9 they are limited in these high-risk populations
owing to being invasive procedures that could result in
further vessel or hepatic injury. Therefore, finding nonin-
vasive optimal biomarkers allowing early detection before
varices formation or rupture to further decrease mortality of
cirrhotic patients remains a critical issue.
In our study, IL-6, IL-27, TNF-a, and VEGF were signifi-
cantly expressed in LC-total and CH-total groups than HG
(Fig. 1), which was in accordance with previous studies
where overexpression of cytokine or chemokine-mediated
immunity could stimulate hepatocyte proliferation with
fibrogenesis development in liver diseases.10e21,27e29elates with p-STAT3 expression and presents high variceal bleeding
icrobiology, Immunology and Infection (2015), http://dx.doi.org/
Figure 4. IL-6 presented the strongest correlation with 3-month (A) and 6-month mortality (B) in cirrhotic patients. * A value of
p < 0.05 was defined as statistically significant.
Table 3 Univariate and multivariate analysis of mortality in cirrhotic patients (N Z 158)
Variable Risk ratio (95% CI) p Risk ratio (95% CI) p
Demographics
Age (>60 y) 1.665 (0.860e3.221) 0.130
Gender (male) 1.027 (0.506e2.081) 0.942
Varices (positive) 1.200 (0.637e2.262) 0.573
Variceal bleeding (positive) 3.520 (1.508e8.218) 0.004* 3.955 (1.109e14.103) 0.034*
IL-6 (>7.10 pg/mL) 4.832 (2.380e9.812) <0.001* 3.805 (1.482e9.766) 0.005*
IL-27 (>1247.5 pg/mL) 2.257 (0.544e9.364) 0.262
TNF-a (>0.12 pg/mL) 1.833 (0.963e3.491) 0.065
VEGF (>35.19 pg/mL) 4.024 (1.250e12.949) 0.020*
AST (>34 IU/L) 2.184 (0.914e5.220) 0.079
ALT (>40 IU/L) 0.824 (0.434e1.563) 0.552
Albumin (>3.5 g/dL) 0.213 (0.102e0.447) <0.001* 0.237 (0.082e0.684) 0.008*
Bilirubin (>2.0 mg/dL) 1.828 (0.966e3.459) 0.064
Cr (>1.3 mg/dL) 1.912 (0.886e4.126) 0.099
INR (>1.7) 2.379 (0.950e5.957) 0.064
Platelet (>130  103/mL) 0.568 (0.271e1.192) 0.135
AFP (>9 ng/mL) 1.007 (0.489e2.075) 0.985
*A value of p < 0.05 was defined as significant.
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Figure 5. Immunohistochemical studies of p-STAT1 and p-STAT3 in three identical cirrhotic tissues. Immunoreactivity exhibited
in nuclei or cytoplasm of hepatocyte was designated Level I (<10%), II (S10% to <25%), or III (S25%) [400 magnification; the
brown cell (arrow) shows positive immunostain] (A). Tissue p-STAT3 presented a positive correlation between increasing immu-
noreactivities levels with IL-6 expressions as compared with p-STAT1 with IL-6 in CH with LC patients (r Z 0.316, p Z 0.022;
r Z 0.137, p Z 0.334, respectively) and in LC patients (r Z 0.737, p Z 0.010; r Z 0.400, p Z 0.223, respectively) (B,C). * A
value of p < 0.05 was defined as statistically significant.
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+ MODELNevertheless, we found upregulated IL-27, TNF-a, and
VEGF levels could not reflect the liver condition under
disease progression in cirrhotic patients. In turn, elevated
IL-6 levels significantly correlated with deteriorating liver
condition (Fig. 2) and three important clinical parameters
evaluating condition severity, including albumin
(r Z 0.346; p < 0.001), bilirubin (r Z 0.271; p Z 0.001),
and INR (r Z 0.308; p < 0.001) (Table 2). These findings
proved the action of IL-6 not only induced liver fibrogenesis
like the other three mediators, but also upregulated thePlease cite this article in press as: Kao J-T, et al., IL-6 significantly corr
with mortality in cirrhotic patients: A cross-sectional study, Journal of M
10.1016/j.jmii.2015.03.001disease process to deteriorate hepatic preservation in
cirrhotic patients.
With deterioration of liver preservation in cirrhotic pa-
tients, the risk of varices formation and severity could be
increased and often threaten patients’ survival owing to
fatal complications.3,31 In this study, we found TNF-a (as
found in previous findings) was significantly expressed in
patients with varices (Fig. 3A) and increased severity
(Grade 0 vs. 1, pZ 0.017)22,23, but it did not correlate with
increased variceal bleeding (Fig. 3B). By contrast, signifi-
cant IL-6 expression not only reflected varices formationelates with p-STAT3 expression and presents high variceal bleeding
icrobiology, Immunology and Infection (2015), http://dx.doi.org/
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+ MODELwith severity (from Grade 0 to 3: 11.57  2.98 vs.
15.30  3.74 vs. 15.08  3.68 vs. 22.09  8.63 pg/mL,
respectively, r Z 0.190 and p Z 0.017), but also increased
bleeding risk (Fig. 3A and B). This proved the finding of prior
studies where IL-6 was overexpressed in the hyperdynamic
circulation and associated with variceal bleeding owing to
increasing gastroduodenal/intestinal permeability in
cirrhotic patients.32,33 Increasing permeability would in-
crease the risk of bacterial infection in bleeding patients,
but our study found insignificant correlation between raised
IL-6 expression and increased bacterial translocation in
bleeding cases. However, higher IL-6 expression was found
in cases with positive bacterial culture (nZ 21) than those
without bacterial culture (n Z 11) (26.19  5.31 vs.
14.60  10.09 pg/mL, p Z 0.270), which could be limited
by cases numbers. In clinical scenarios, hepatic preserva-
tion frequently decides patient’s outcome. In this study,
over-expression of IL-6 also increased 3-month (Fig. 4A), 6-
month (Fig. 4B), and 24-month mortality (Table 3). Its
importance was equal or probably high for some important
clinical features, such as variceal bleeding, lower albumin,
higher bilirubin, and prolonged INR levels (Table 3). These
findings identified upregulation of IL-6, which reflected
more active hepatic severity,17-21 development of varices
with bleeding, as well as probably increased bacterial
translocation through upregulation of permeability due to
portal hypertension while deteriorating hepatic preserva-
tion in cirrhotic patients.4e6,32,33
Of the various downstream signaling targets of these
mediators’ profile, STAT and its family members, particu-
larly in STAT1 and STAT3 proteins, played an important role
in the pathogenesis of liver diseases.21 However, the clin-
ical relevance among these mediators with the STAT1 and
STAT3 proteins remains not well understood and needs to
be further elucidated in patients with different clinical
stages of liver diseases. As for the resulting findings, only IL-
6 significantly correlated with fibrosis severity in 52 biopsy
patients (r Z 0.313, p Z 0.024). Also, we found p-STAT3
not only expressed a higher immunostaining rate than p-
STAT1 (32/52 vs. 19/52, p Z 0.003), but also its immuno-
reactivities levels were associated with IL-6 expression as
compared with three mediators in all patients (r Z 0.116,
p Z 0.239 in IL-27; r Z 0.228, p Z 0.105 in TNF-a;
r Z 0.329, p Z 0.017 in VEGF) and particularly in LC pa-
tients (r Z 0.078, p Z 0.820; r Z 0.145, p Z 0.670;
r Z 0.142, p Z 0.678, respectively), (Fig. 5B and C).
In the current study, we failed to demonstrate finding of
all-participant liver tissues particularly in cirrhotic patients,
and the limitation of cases numbers resulted in insignificant
difference between p-STAT3 expression and the varices
severity. However, this is limited based on ethical and safety
considerations because patients with decompensation usu-
ally have high hemorrhagic risk. Additionally, b-blocker
medication might benefit cirrhotic patients with variceal
bleeding, but there was no significant difference between
patients with or without b-blocker medication and bleeding
(9/25 vs. 6/23, pZ 1.000) as well as mortality (3-month: 3/
25 vs. 9/67, pZ 1.000; 6-month: 4/25 vs. 11/67, pZ 1.000;
time of study ending: 13/46 vs. 12/46, p Z 1.000) in this
study. Our study provided much useful information in liver
diseases but was limited in a cross-sectional finding, which
might have misleading considerations; therefore, furtherPlease cite this article in press as: Kao J-T, et al., IL-6 significantly corr
with mortality in cirrhotic patients: A cross-sectional study, Journal of
10.1016/j.jmii.2015.03.001cohort studies need to be adopted in the future. The fluc-
tuation of serum IL-6, IL-27, TNF-a, and VEGF concentra-
tions in the host might be argued, but these molecules were
examined from plasma in our study that were not affected
by the amount of time between blood sampling and centri-
fugation according to a previous study.34
Based on these clinical findings in this study, we clearly
demonstrated that plasma IL-6 not only plays the role of
determined promoter in disease progression aswell as varices
development with severity, but also affects cirrhotic patient
survival. The mechanism IL-6 might act on liver diseases
through upregulation of p-STAT3 rather than p-STAT1 in the
real world. We therefore believe through the generalizability
of the study result that detection of plasma IL-6 expression
before invasive procedures, such as esophagogas-
troduodenoscopy and hepatic venous pressure gradient
monitoring, might provide clinicians with an effective refer-
ence allowing varices development and rupture to be earlier
diagnosed.35 Furthermore, it might create an attractive
agent to prevent patient mortality in the future.Conflicts of interest
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